These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17690571)

  • 1. Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy.
    Brown TT; Chu H; Wang Z; Palella FJ; Kingsley L; Witt MD; Dobs AS
    AIDS; 2007 Aug; 21(13):1731-8. PubMed ID: 17690571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
    Valantin MA; Lanoy E; Bentata M; Kalmykova O; Boutekadjirt A; Allavena C; Rozenbaum W; Peytavin G; Amellal B; Calvez V; Costagliola D; Katlama C;
    HIV Med; 2008 Oct; 9(8):625-35. PubMed ID: 18624724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.
    Guaraldi G; Squillace N; Stentarelli C; Orlando G; D'Amico R; Ligabue G; Fiocchi F; Zona S; Loria P; Esposito R; Palella F
    Clin Infect Dis; 2008 Jul; 47(2):250-7. PubMed ID: 18532884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutrition.
    Maia BS; Engelson ES; Wang J; Kotler DP
    Clin Nutr; 2005 Dec; 24(6):971-8. PubMed ID: 16095765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
    Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M
    Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal anthropometric changes in HIV-infected and HIV-uninfected men.
    Brown T; Wang Z; Chu H; Palella FJ; Kingsley L; Witt MD; Dobs AS
    J Acquir Immune Defic Syndr; 2006 Nov; 43(3):356-62. PubMed ID: 16980910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
    Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study.
    Tien PC; Schneider MF; Cole SR; Levine AM; Cohen M; DeHovitz J; Young M; Justman JE
    AIDS; 2007 Aug; 21(13):1739-45. PubMed ID: 17690572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fat redistribution syndrome in patients infected with HIV: measurements of body shape abnormalities.
    Gerrior J; Kantaros J; Coakley E; Albrecht M; Wanke C
    J Am Diet Assoc; 2001 Oct; 101(10):1175-80. PubMed ID: 11678488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.
    Ware LJ; Jackson AG; Wootton SA; Burdge GC; Morlese JF; Moyle GJ; Jackson AA; Gazzard BG
    Br J Nutr; 2009 Oct; 102(7):1038-46. PubMed ID: 19480729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
    Nolan D; Hammond E; James I; McKinnon E; Mallal S
    Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.
    Moreno-Torres A; Domingo P; Pujol J; Blanco-Vaca F; Arroyo JA; Sambeat MA
    Antivir Ther; 2007; 12(2):195-203. PubMed ID: 17503662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
    Blümer RM; van Vonderen MG; Sutinen J; Hassink E; Ackermans M; van Agtmael MA; Yki-Jarvinen H; Danner SA; Reiss P; Sauerwein HP
    AIDS; 2008 Jan; 22(2):227-36. PubMed ID: 18097225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.
    Martínez E; Domingo P; Ribera E; Milinkovic A; Arroyo JA; Conget I; Pérez-Cuevas JB; Casamitjana R; de Lazzari E; Bianchi L; Montserrat E; Roca M; Burgos R; Arnaiz JA; Gatell JM
    Antivir Ther; 2003 Oct; 8(5):403-10. PubMed ID: 14640387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
    Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy.
    Lindsey JC; Malee KM; Brouwers P; Hughes MD;
    Pediatrics; 2007 Mar; 119(3):e681-93. PubMed ID: 17296781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.